Cargando…
Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
Sarcoid Associated Pulmonary Hypertension (SAPH) is a common complication of sarcoidosis and is associated with poor prognosis. SAPH can be due to multiple synergistic mechanisms and current therapeutic strategies treat systemic sarcoidosis and pulmonary hypertension separately. Several studies have...
Autores principales: | Abston, Eric, Hon, Stephanie, Lawrence, Romy, Berman, Jeffrey, Govender, Praveen, Farber, Harrison W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569547/ https://www.ncbi.nlm.nih.gov/pubmed/33093789 http://dx.doi.org/10.36141/svdld.v37i2.9343 |
Ejemplares similares
-
Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020) -
Stability-Indicating RP-HPLC Method for the Determination of Ambrisentan and Tadalafil in Pharmaceutical Dosage Form
por: Patel, Jayvadan K., et al.
Publicado: (2014) -
Ambrisentan for the treatment of pulmonary arterial hypertension
por: Casserly, Brian, et al.
Publicado: (2009) -
Hepatic safety of ambrisentan alone and in combination with
tadalafil: a post-hoc analysis of the AMBITION trial
por: Patel, Krishna R., et al.
Publicado: (2018) -
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)